Physician profile
Lee Peng
NPI 1437149507
$1,301.21
in general payments reported to CMS, 2019-2025
18 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $49.77 · 2022: $21.70 · 2023: $29.26 · 2024: $170 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $449.46 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $190.19 | 2021-2025 | |
| Amgen INC. | $139.29 | 2025 | Uplizna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.21 | 2024-2025 | Xifaxan, Relistor |
| Abbvie INC. | $107.94 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $33.90 | 2024 | Iqirvo |
| Orphalan INC | $33.24 | 2024 | Cuvrior |
| Dynavax Technologies Corporation | $32.93 | 2025 | Heplisav-B |
| Ardelyx, INC. | $23.16 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $22.55 | 2025 | Vowst |
| Olympus America INC. | $21.01 | 2025 | Evis Exera III Colonovideoscope |
| Cook Medical LLC | $17.79 | 2025 | Hemospray |
| Mallinckrodt Hospital Products INC. | $16.10 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $15.78 | 2024 | Delstrigo, Isentress, Pifeltro |
| Phathom Pharmaceuticals, INC. | $15.65 | 2024 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $15.62 | 2025 | Recorlev |
| Novo Nordisk INC | $14.86 | 2025 | Wegovy |
| Corcept Therapeutics | $14.53 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.